[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577694":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":59,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":26,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"The University of Texas Medical Branch, Galveston","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PLUS Group","EXPERIMENTAL","Treatment with active H1 antihistamine and administered active H2 antihistamine and using cromolyn sodium PLUS (-PLUS active H1 antihistamine, plus active famotidine and active cromolyn sodium)",[13],"Combination Product: Famotidine and 4% topical cromolyn sodium",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Treatment with active H1 antihistamine plus administration of placebo famotidine and placebo cromolyn sodium.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"COMBINATION_PRODUCT","Famotidine and 4% topical cromolyn sodium","Patients will be instructed to take a 20mg famotidine capsule twice daily, and to use the lotion (4% cromolyn sodium) twice daily.",[9],null,{"type":6,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Placebo",[15],[31],{"name":32,"affiliation":33,"role":34},"Celeste Finnerty, PhD","University of Texas Medical Branch, Galveston","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Lindsey Allen, RN","CONTACT","409-266-2678","listurm@utmb.edu",[42],{"facility":33,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Galveston","Texas","77555","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-94.7977,29.30135,{"lat":53,"lon":52},[56],{"name":32,"role":38,"phone":57,"phoneExt":26,"email":58},"409-692-9036","ccfinner@utmb.edu",{"type":60,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[62],{"name":63,"class":6},"University of Texas","100577694","phase-3-novel-strategies-for-reducing-burn-scar-itch-100577694",false,"NCT06801626","Novel Strategies for Reducing Burn Scar Itch","Inclusion Criteria:\n\nParticipants must meet all the inclusion criteria in order to be eligible to participate in the study.\n\n* Participant has provided informed consent in a manner approved by the IRB and is willing and able to comply with the trial procedures.\n* Adults: ≥18 to \\\u003C80 years of age.\n* Has an itchy burn scar.\n\nExclusion Criteria:\n\nParticipants meeting any of the exclusion criteria at baseline will be excluded from study participation.\n\n* Failure to obtain consent or unable to return for follow up assessments.\n* Patient is unable to follow the protocol required assessments.\n* Member of a vulnerable class (e.g., prisoners, pregnant participant, etc.).\n* Any medical condition that, in the opinion of the investigator or physician, would place the participant at increased risk for participation.\n* Concurrent participation in another interventional clinical trial (to avoid confounding factors that may influence outcomes).\n* History of prior non-compliance or the presence or history of psychiatric condition (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the participant to comply with the study procedures or follow the investigators instructions.\n* Age \\\u003C 18 or ≥ 80 years.\n* Taking one of the following medications: cefuroxime, dasatinib, delavirdine, neratinib, pazopanib, risedronate, or tizanidine.\n* Has a pre-existing inflammatory or itchy skin disease.\n* Is taking an H2 antihistamine for another indication.","ALL","18 Years","80 Years",{"count":74,"type":75},44,"ESTIMATED","INTERVENTIONAL",[78],"PHASE3","The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.",[81,82,83],"Burn Scar","Itch Scarring","Wound",[85,86,87,88],"Itch","Burn","Diphenhydramine","Famotidine","2025-09-18",{"date":91,"type":92},"2025-09-24","ACTUAL",{"date":94,"type":92},"2025-03-01",{"date":96,"type":75},"2027-11-01",{"name":5,"class":6},1]